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Dimethyl Sulfoxide Inhibits Tissue Factor Expression,
Thrombus Formation, and Vascular Smooth Muscle
Cell Activation
A Potential Treatment Strategy for Drug-Eluting Stents
Giovanni G. Camici, BSc; Jan Steffel, MD; Alexander Akhmedov, PhD; Nicola Schafer, BSc;
Jeannette Baldinger, BSc; Urs Schulz, BSc; Kushiar Shojaati, PhD; Christian M. Matter, MD;
Zhihong Yang, MD; Thomas F. Lüscher, MD; Felix C. Tanner, MD
Background—Subacute stent thrombosis is a major clinical concern, and the search for new molecules to cover stents
remains important. Dimethyl sulfoxide (DMSO) is used for preservation of hematopoietic progenitor cells and is infused
into patients undergoing bone marrow transplantation. Despite its intravenous application, the impact of DMSO on
vascular cells has not been assessed.
Methods and Results—In human endothelial cells, monocytes, and vascular smooth muscle cells (VSMC), DMSO
inhibited tissue factor (TF) expression and activity in response to tumor necrosis factor- or thrombin in a
concentration-dependent manner. DMSO did not exert any toxic effects as assessed by phase-contrast microscopy,
trypan blue exclusion, and lactate dehydrogenase release. Real-time polymerase chain reaction revealed that inhibition
of TF expression occurred at the mRNA level. This effect was mediated by reduced activation of the mitogen-activated
protein kinases c-Jun terminal NH2 kinase (516%; P0.0005) and p38 (503%; P0.0001) but not p44/42 (PNS).
In contrast to TF, DMSO did not affect expression of TF pathway inhibitor or plasminogen activator inhibitor-1. In vivo,
DMSO treatment suppressed TF activity (41%; P0.002) and prevented thrombotic occlusion in a mouse carotid artery
photochemical injury model. DMSO also inhibited VSMC proliferation (70%; P0.005) and migration (77%;
P0.0001) in a concentration-dependent manner; moreover, it prevented rapamycin and paclitaxel-induced upregula-
tion of TF expression.
Conclusions—DMSO suppresses TF expression and activity, as well as thrombus formation; in addition, it inhibits VSMC
proliferation and migration. Given its routine use in modern clinical practice, we propose DMSO as a novel strategy for
coating drug-eluting stents and treating acute coronary syndromes.
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Dimethyl sulfoxide (DMSO) is used for preservation ofhematopoietic progenitor cells and therefore is infused
into patients undergoing bone marrow or stem cell transplan-
tation.1 In this context, peak plasma concentrations reach
values as high as 20 mmol/L. DMSO is also used as a solvent
for chemotherapeutic drugs and, due to its antiinflammatory
properties, has been successfully used in humans for treating
rheumatic,2 pulmonary,3 gastrointestinal,4,5 neurological,6,7
urinary,8 and dermatological9,10 disorders. DMSO further
exhibits protective effects in animal models of middle cere-
bral artery occlusion,11 cerebral hypoperfusion–related neu-
ronal death,12 mercuric chloride–induced kidney injury,13 and
chemical liver injury.14 A recent report proposed that DMSO
reduces ischemic brain damage through both antiinflamma-
tory and free radical scavenging properties.11 Despite all this
information, the impact of DMSO on cardiovascular disor-
ders has not been assessed.
Tissue factor (TF) is a key protein in the activation of
coagulation.15 Plaque rupture induces arterial thrombosis and is
the main cause of acute coronary syndromes such as unstable
angina and acute myocardial infarction. TF plays a major role in
determining plaque thrombogenicity,16 because its expression is
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upregulated in different cell types within the atherosclerotic
vessel wall, and it is exposed to the bloodstream after plaque
rupture. Many inflammatory mediators are indeed capable of
inducing TF expression in monocytes, macrophages, endothelial
cells, and vascular smooth muscle cells (VSMCs)16; not surpris-
ingly, experimental evidence has revealed an important contri-
bution of TF to the pathogenesis of subacute stent thrombosis
and restenosis after balloon angioplasty or stent deployment.16
As a consequence, recent efforts have focused on the therapeutic
implications of TF inhibition.16 Because intravenous delivery of
DMSO has become a recognized practice in clinical oncology
owing to the increasing use of bone marrow transplants, the
present study was designed to investigate the impact of DMSO
on TF expression and thrombosis and on activation of VSMCs.
Methods
Cell Culture
Human aortic endothelial cells (HAECs) and VSMCs (Clonetics,
Allschwil, Switzerland) were cultured as described previously.15
Human peripheral blood myocytes (THP)-1 cells (LGC Promochem,
Molsheim, France) were cultured according to the supplier’s recom-
mendation. Adhering cells were grown to confluence in 3-cm dishes
and rendered quiescent for 24 hours before stimulation with 5 ng/mL
tumor necrosis factor- (TNF-) or 1 U/mL thrombin (both from
Sigma, Basel, Switzerland). Cells were pretreated with DMSO
(Sigma) for 1 hour before stimulation. To block the mitogen-acti-
vated protein (MAP) kinase p38, p44/42 (ERK), or c-Jun terminal
NH2 kinase (JNK), cells were treated with SB203580 (Sigma),
PD98059 (Cell Signaling, Danvers, Mass), or SP600125 (Calbio-
chem, Lucerne, Switzerland) for 60 minutes before stimulation.
Rapamycin and paclitaxel (both from Sigma) were added to the cells
1 hour before thrombin (1 U/mL) stimulation. To assess cytotoxicity,
a colorimetric assay for detection of lactate dehydrogenase (LDH)
was used according to the manufacturer’s recommendations (Roche,
Basel, Switzerland); in addition, a trypan blue exclusion assay (0.4%
solution, Sigma) and morphological examination by phase-contrast
microscopy (Leica, Glattbrugg, Switzerland) were performed.
Western Blot Analysis
Protein expression was determined by Western blot analysis as described
previously.17 Cells were lysed in 50 mmol/L Tris buffer; 30-g samples
Figure 1. DMSO inhibits TF expression and activity. A, DMSO inhibits TNF-–induced TF expression of HAECs in a concentration-
dependent manner. Values are given as percent of stimulation with TNF- alone. *P0.001, ** P0.0001 vs TNF- alone. B, DMSO
inhibits thrombin-induced TF expression of HAECs in a concentration-dependent manner. Values are given as percent of stimulation
with thrombin alone. *P0.001, ** P0.0001 vs thrombin alone. C, DMSO inhibits TNF-–induced TF surface activity of HAECs. Values
are given as percent of stimulation with TNF- alone. ** P0.0001 vs TNF- alone. D, DMSO inhibits TNF-–induced TF expression in
a concentration-dependent manner in HAECs, human monocytic cells (THP-1), and human aortic VSMCs. Values are representative of
at least 3 different experiments; all blots are normalized to GAPDH expression.
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were loaded, separated by 10% SDS-PAGE, and transferred to a polyvi-
nylidene fluoride membrane (Millipore, Volketswil, Switzerland) by semi-
dry transfer.18 Equal loading was confirmed by Ponceau S staining.
Antibodies against human TF, TF pathway inhibitor (TFPI; both from
American Diagnostica, Stamford, Conn), and plasminogen activator inhib-
itor-1 (PAI-1; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) were used
at 1:2000 dilution. Antibodies against phosphorylated p38, phosphorylated
ERK, and phosphorylated JNK (all from Cell Signaling) were used at
1:1000, 1:5000, and 1:1000 dilution, respectively. Antibodies against total
p38, total ERK, and total JNK (all fromCell Signaling)were used at 1:2000,
1:10 000, and 1:1000 dilution, respectively. Blots were normalized to
GAPDH expression (1:10 000 dilution, Sigma). Representative blots are
shown; bars represent at least 3 different experiments.
TF Activity
TF cell surface and tissue activity was analyzed in HAEC and mouse
carotid artery homogenates, respectively, with a colorimetric assay (Amer-
ican Diagnostica) according to the manufacturer’s recommendations with
some modifications as described previously.15 Cells were grown in 6-well
plates; after stimulation, cells were washed twice with phosphate-buffered
saline (PBS) followed by incubation with human factor VIIa (FVIIa) and
factor X (FX) at 37°C, which allowed the formation of TF/FVIIa complex
at the cell surface. Right carotid arterieswere homogenized in 50Lof lysis
buffer (50 mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100, pH 7.4;
Union Carbide Corp, Danbury, Conn) 2 hours after intraperitoneal applica-
tion of DMSO or vehicle and left to stand on ice for 30 minutes. TF/FVIIa
complex converted human FX to factor Xa, which was measured by its
ability to metabolize a chromogenic substrate. A standard curve with
lipidated humanTFwas performed to ensure thatmeasurements were taken
in the linear range of detection.
Real-Time Polymerase Chain Reaction Analysis
Real-time polymerase chain reaction (PCR) analysis was performed
as described previously.19 An MX3000P PCR cycler (Stratagene,
Figure 2. Lack of DMSO-induced toxic-
ity. A, Incubation with DMSO for 6 hours
does not affect cell morphology (magniﬁ-
cation 20). LDH release (B) and the
number of trypan blue–positive cells (C)
remain unaffected by different DMSO
concentrations as well. Values are given
as percent of stimulation with TNF-
alone.
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Amsterdam, Netherlands) was used according to the manufacturer’s
instructions. All PCR experiments were performed in triplicate with
the SYBR Green JumpStart kit (Sigma). Each reaction (25 L)
contained 2 L of cDNA, 1 pmol of each primer, 0.25 L of internal
reference dye, and 12.5 L of JumpStart Taq ReadyMix (containing
buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase, and
JumpStart Taq antibody). The following primers were used: TF (F3):
sense primer: 5-TCCCCAGAGTTCACACCTTACC-3 (bases 508
to 529 of F3 cDNA; National Center for Biotechnology Information
No. NM 001993), antisense primer: 5-TGACCACAAATACCA-
CAGCTCC-3 (bases 892 to 913 of F3 cDNA; National Center for
Biotechnology Information No. NM 001993); human L28: sense
primer: 5-GCATCTGCAATGGATGGT-3, antisense primer: 5-
TGTTCTTGCGGATCATGTGT-3. The amplification program
consisted of 1 cycle at 95°C for 10 minutes, followed by 40 cycles
with a denaturing phase at 95°C for 30 seconds, an annealing phase
at 60°C for 1 minute, and an elongation phase at 72°C for 1 minute.
PCR products were analyzed on an ethidium bromide–stained 1%
agarose gel, and a melting curve analysis was performed after
amplification to verify the accuracy of the amplicon. In each
real-time PCR run for F3 and L28, a calibration curve was included
that was generated from serial dilutions of the respective purified
amplicons.
Proliferation and Migration of Human
Aortic VSMCs
For proliferation, VSMCs were seeded at a density of 10 000 cells
per 35-mm dish and cultured for 24 hours in Dulbecco modified
Eagle medium (DMEM) with 10% fetal calf serum (FCS). Succes-
sively, cells were serum withdrawn in DMEM with 1% FCS for 48
hours. Cells were then maintained in DMEM with 10% FCS in the
presence of different DMSO concentrations. Medium and appropri-
ate DMSO concentrations were replaced daily, and cell number was
determined after 3 days with a hemocytometer (Assisten, Sondheim,
Germany).
For migration, VSMCs were seeded at a density of 250 000 cells
per 150-mm dish and cultured for 24 hours in DMEM with 10%
FCS. Cells were then harvested and resuspended (500 000 cells/mL)
for analysis of migration in response to platelet-derived growth
factor 10 ng/mL. Migration was assessed in a modified Boyden
chamber system (Neuro Probe Inc, Gaithersburg, Md) as described
previously.20 The number of migrated cells was determined by
staining (Diff-Quik; Dade Diagnostics Inc, Aguada, Puerto Rico) and
counting the cells at 400 magnification (Leica) on 4 random
microscopic fields per group.
Carotid Artery Thrombosis Model
C57BL/6 mice (6 to 8 weeks old; Charles River Laboratories,
Sulzfeld, Germany) weighing an average of 232 g were anesthe-
tized with intraperitoneal injection of 2 mg of sodium pentobarbital
(Butler, Columbus, Ohio) as described previously.21,22 Rose bengal
(Fisher Scientific, Fair Lawn, NJ) was diluted to 10 mg/mL in PBS
and then injected into the tail vein in a volume of 0.12 mL at a
concentration of 50 mg/kg with a 27-gauge Precision Glide needle
with a 1-mL latex free syringe (Becton Dickinson, Franklin Lakes,
NJ). Mice were secured in a supine position, placed under a
dissecting microscope (Olympus C-4040 Zoom; spatial resolution
4.1 megapixels, Olympus Schweiz, AG, Switzerland), and the right
common carotid artery was exposed after a midline cervical incision.
A Doppler flow probe (model 0.5 VB, Transonic Systems, Ithaca,
NY) was then applied and connected to a flowmeter (Transonic,
model T106). Six minutes after rose bengal injection, a 1.5-mW
green light laser (540 nm; Melles Griot, Carlsbad, Calif) was applied
to the desired site of injury at a distance of 6 cm for 60 minutes or
until thrombosis occurred. From the onset of injury, blood flow in the
vessel was monitored for 120 minutes, at which time the experiment
was terminated. Occlusion was defined as a flow of0.1 mL/min for
at least 1 minute.23 Mice were divided into 3 groups: DMSO
intraperitoneal (1 hour before surgery, 3.8 mL/kg of 40% DMSO in
PBS), PBS intrapenitoneal (1 hour before surgery, 3.8 mL/kg of
PBS), and an additional control without laser injury. In a separate set
of experiments, DMSO or vehicle was applied 5 minutes after onset
of laser injury.
Statistical Analysis
Data are presented as meanSEM. Statistical analysis was per-
formed by 2-tailed unpaired Student t test or ANOVA as appropriate.
A probability value of 0.05 was considered significant.
The authors had full access to the data and take full responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
Results
DMSO Inhibits TF Protein Expression
and Activity
Stimulation of HAECs with TNF- (5 ng/mL) resulted in a
19-fold increase in TF expression (n4; P0.0001; Figure 1A);
similarly, thrombin (1 U/mL) induced a 24-fold increase of TF
(n4; P0.0001; Figure 1B). When cells were pretreated with
increasing concentrations of DMSO (0.1% to 1.0%), TF induc-
Figure 3. DMSO inhibits TF mRNA expression. A, Real-time
PCR demonstrates increased TF mRNA expression after 2 hours
of stimulation with TNF-. DMSO inhibits this effect. Values are
given as percent of stimulation with TNF- alone. *P0.001 vs
TNF- alone. B, CT values (an approximation of transcription
based on the change in threshold values for control vs target
cells [the cycle number at which ﬂuorescence crosses the
threshold of logarithmic increases in cDNA concentration]) con-
ﬁrm that DMSO decreases TNF-–induced TF mRNA expres-
sion. **P0.0001 vs TNF- alone. All values are representative
of 4 different experiments and are normalized to L28 mRNA.
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tion by both TNF- and thrombin was inhibited in a
concentration-dependent manner (n4; P0.0001 for TNF- or
thrombin alone versus 1.0% DMSO; Figures 1A and 1B). This
effect was paralleled by a similar inhibition of TF surface
activity (n4; P0.0001 for TNF- alone versus 1.0% DMSO;
Figure 1C). When DMSO was applied 5 minutes after stimula-
tion with TNF-, inhibition of TF induction was similar to that
observed with DMSO pretreatment (806% inhibition versus
TNF- alone; n4; P0.0001; data not shown). In THP-1 cells,
stimulation with TNF- (5 ng/mL) induced a 10-fold increase in
TF expression (n4; P0.0001), which was inhibited by
DMSO (n4; P0.005 for TNF- alone versus 1.0% DMSO;
Figure 1D). In VSMCs, the 3.5-fold increase in TNF-–induced
TF expression (n4; P0.005) was inhibited as well by DMSO
(n4; P0.05 for TNF- alone versus 1.0% DMSO; Figure
1D).
DMSO Does Not Exert Toxicity in Human
Vascular Cells
To assess potential toxic effects of DMSO, HAECs were
incubated with 1.0% DMSO for 6 hours, and a morphological
examination was performed. No changes in cell morphology
were observed when cells with or without treatment were
compared (Figure 2A). In addition, cell death was assessed by
both LDH release and trypan blue exclusion in HAECs;
again, no signs of toxicity were detected by either method
(n4; PNS; Figures 2B and 2C).
DMSO Inhibits TF mRNA Expression
Peak induction of TF mRNA occurs 2 hours after stimulation
with TNF-.19 Real-time PCR analysis confirmed a 10-fold
induction of TF mRNA expression after 2 hours of TNF-
stimulation in HAECs (n3; P0.001; Figure 3A). Treat-
ment with 1.0% DMSO inhibited TF mRNA expression by
657% (n3; P0.0001 for TNF- alone versus 1.0%
DMSO; Figures 3A and 3B).
DMSO Impairs TF Expression via MAP
Kinase Inhibition
To assess whether DMSO affects MAP kinase activation,
HAECs were examined at different time points after stimu-
lation. JNK, p38, and ERK were transiently activated by
TNF- (Figure 4A). Maximal phosphorylation occurred after
15 minutes and returned to basal levels within 60 minutes
(Figure 4A). DMSO inhibited phosphorylation of JNK and
p38 by 50% while leaving activation of ERK unaltered
(Figure 4A). Indeed, maximal phosphorylation of JNK was
decreased by 516% (n4; P0.0005; Figure 4B) and that
of p38 by 503% (n4; P0.0001; Figure 4B); in contrast,
maximal activation of ERK was not reduced significantly
Figure 4. DMSO inhibits MAP kinase activation.
A, Stimulation with TNF- leads to transient
phosphorylation (Pho) of the MAP kinases JNK,
p38, and ERK. DMSO inhibits phosphorylation
of JNK and p38 but not ERK. Total (Tot) levels
of JNK, p38, and ERK remain unchanged. B,
DMSO strongly inhibits phosphorylation of JNK
and p38 but not ERK. Average values of 4 dif-
ferent experiments. **P0.001 for JNK and p38
vs TNF- alone. MAPK indicates MAP kinase. C,
SP600125 (10	6 mol/L), SB203580 (10	5 mol/L),
and PD98059 (310	6 mol/L), speciﬁc inhibitors
of JNK, p38, and ERK, respectively, inhibit TNF-
–induced TF expression. *P0.001 vs TNF-
alone. Blots are representative of at least 3 dif-
ferent experiments.
5
ht
tp
://
do
c.
re
ro
.c
h
(n4; PNS; Figure 4B). No change in total expression of
JNK, p38, or ERK was observed at any time point with or
without DMSO. To verify the involvement of MAP kinases in
TNF-–induced TF expression under our experimental con-
ditions, the effect of MAP kinase inhibitors on TF expression
was examined in HAECs. SP600125, SB203580, and
PD98059, which specifically inhibit JNK, p38, and ERK,
respectively, significantly impaired TF induction after TNF-
stimulation (n4; P0.001 for TNF- alone versus each
inhibitor; Figure 4C).
DMSO Does Not Affect TFPI and
PAI-1 Expression
The effect of DMSO on the physiological inhibitor of TF,
TFPI, and on the antifibrinolytic factor PAI-1 was assessed.
Treatment of TNF-–stimulated HAECs with 1% DMSO did
not affect TFPI expression (n4; PNS; Figure 5A). Simi-
larly, treatment of TNF-–stimulated HAECs with 1.0%
DMSO did not alter PAI-1 expression (n4; PNS; Figure
5B).
DMSO Suppresses TF Activity and Prevents
Arterial Thrombosis In Vivo
Treatment with DMSO (3.8 mL/kg of 40% DMSO in PBS,
corresponding to 80 mg/kg DMSO) reduced TF activity in
mouse carotid artery in vivo (n3; P0.002 for vehicle
[PBS] versus DMSO; Figure 6A). Photochemically induced
arterial injury is dependent on TF and is an established model
of arterial thrombosis.21–24 Initial blood flow in vehicle
(PBS)-treated mice equaled 1.250.15 mL/min (n5); these
mice developed thrombotic occlusion within 1 hour after
onset of injury (mean occlusion time 639 minutes; n5;
P0.0001 for initial versus final blood flow; Figure 6B).
During injury, it was evident from transient reductions in
flow that a dynamic state of thrombus formation and lysis
occurred during the short interval before complete occlusion.
Cessation of blood flow coincided with the appearance of a
faint white occlusive defect that was visible through the
microscope in the lumen of the artery. DMSO (3.8 mL/kg of
40% DMSO in PBS, corresponding to 80 mg/kg DMSO)–
treated mice exhibited similar initial blood flow (1.140.19
mL/min; n5; PNS for vehicle versus DMSO) but did not
develop thrombotic occlusion. Indeed, 120 minutes after
onset of injury, blood flow in DMSO-treated mice was still
very high (0.750.15 mL/min; n5; P0.01 for vehicle
versus DMSO). However, DMSO-treated mice exhibited a
small but significant decrease in blood flow during the
120-minute observation period compared with control mice
that did not undergo photochemical injury (n5; P0.05).
Blood flow in the latter did not change significantly during
the 120-minute observation period (initial flow 1.120.17
mL/min; final flow 0.940.09 mL/min; n5; PNS for
initial versus final blood flow). When intraperitoneal appli-
cation of DMSO or vehicle was performed 5 minutes after the
onset of laser injury, DMSO still prevented thrombotic
occlusion of the carotid artery in 50% of mice (n6; data not
shown).
DMSO Inhibits Proliferation and Migration of
Human VSMCs
Treatment with DMSO inhibited VSMC proliferation in
response to 20% FCS in a concentration-dependent fashion
(n4; P0.05; Figure 7A). Likewise, DMSO inhibited
VSMC migration in response to 10 ng/mL platelet-derived
growth factor-BB (n4; P0.05; Figure 7B).
Both rapamycin and paclitaxel are known to enhance
thrombin-induced TF expression.19,25 To determine whether
DMSO can prevent this effect, HAECs were incubated with
either drug with or without DMSO (Figure 7C). Rapamycin
(10	7 mol/L) and paclitaxel (10	5 mol/L) enhanced thrombin-
induced TF expression by 241.954.61% (n4; P0.05
versus thrombin alone; Figure 7C) and 18435.3% (n4;
P0.05 versus thrombin alone; Figure 7C), respectively.
DMSO blunted the effect of rapamycin and paclitaxel on TF
expression (n4; P0.0001 versus thrombin plus rapamy-
cin or thrombin plus paclitaxel; Figure 7C).
Figure 5. DMSO does not affect TFPI and PAI-1 expression. A,
DMSO does not affect TFPI expression. Values are given as per-
cent of TNF- alone. PNS vs TNF- alone. B, DMSO does not
affect TNF-–induced PAI-1 expression. Values are given as
percent of TNF- alone. PNS vs TNF- alone. Blots are repre-
sentative of at least 3 different experiments. **P0.001.
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This study demonstrates that DMSO inhibits TF expression
and activity via reduced activation of the MAP kinases JNK
and p38. Consistent with this observation, DMSO suppresses
TF activity and protects against thrombotic occlusion in vivo.
The study also demonstrates that DMSO inhibits proliferation
and migration of VSMCs; furthermore, it prevents TF induc-
tion in response to rapamycin and paclitaxel. This profile
renders DMSO ideally suitable for application on drug-
eluting stents and for the treatment of acute coronary
syndromes.
DMSO treatment did not exert any toxic effect even at the
highest concentration used (1.0%, equal to 12.6 mmol/L). An
extensive study in human endothelial cells also did not
demonstrate any toxic effects of DMSO even at concentra-
tions well above those used in the present study.26 Moreover,
DMSO has been routinely used to trigger in vitro cellular
differentiation at concentrations as high as 1.25%
(15.7 mmol/L).27 Thus, the DMSO concentrations applied in
the present study are clearly below those used to induce
cellular differentiation.
Thrombin and TNF- induced TF expression in HAECs
with similar potencies, and incubation with DMSO sup-
pressed this effect irrespective of the stimulus. Furthermore,
DMSO reduced TNF-–induced TF expression not only in
HAECs but also in THP-1 cells and VSMCs, which indicates
that the effect on TF occurs regardless of the cell type.
Therefore, the protective action of DMSO is restricted neither
to a specific stimulus nor to a specific vascular cell type.
Activation of MAP kinases mediates TF expression in
response to several stimuli.15,18,28,29 Indeed, JNK, p38, and
ERK were transiently activated in HAECs after stimulation
with either TNF- or thrombin. Treatment with DMSO
impaired TF expression by specifically decreasing phosphor-
ylation of JNK and p38 but not ERK; hence, inhibition of
these 2 MAP kinases suppressed TF expression in a potent
manner. In line with this observation, pharmacological inhi-
bition of the 2 MAP kinases induces a more pronounced
reduction of TF expression than inhibition of 1 MAP kinase
alone. Consistent with inhibition of MAP kinases, DMSO
promoted a strong reduction in TNF-–induced TF mRNA
levels. Thus, the inhibitory action of DMSO is related to a
specific inhibition of MAP kinase activation.
TF activity is counterbalanced by its endogenous inhibitor
TFPI; the balance of these 2 factors is essential in determining
thrombus formation.30 Treatment with DMSO did not affect
TFPI expression, which indicates that the antithrombotic
action of DMSO on TF expression is not compensated by a
concomitant reduction in TFPI expression. PAI-1 is a serpin
that suppresses fibrinolysis by inhibiting the activity of
plasminogen activator. A recent report demonstrated that
DMSO is able to reduce interleukin-1–induced PAI-1 expres-
sion in rat microvascular endothelial cells.31 In contrast, we
did not observe any effect of DMSO on PAI-1 expression in
TNF-–stimulated HAECs; this difference may be related to
the different species, the different origin of the cells, or the
different stimuli used for induction. Thus, the inhibitory
action of DMSO on TF expression does not appear to be
modulated by concomitant effects on TFPI or PAI-1.
It is generally accepted that thrombus formation is trig-
gered by TF.32–34 Photochemical injury was selected as a
model of thrombosis because it is an established protocol for
examining TF-dependent thrombosis in vivo22; moreover,
this procedure does not require intra-arterial invasion.24,35 We
observed that thrombotic occlusion after injury was prevented
in DMSO-treated mice, which indicates that treatment with
DMSO prevents thrombus formation in vivo. Indeed, inhibi-
tion of TF activity in the mouse carotid artery within 2 hours
of DMSO administration was confirmed and thus is the most
likely explanation for the effect of DMSO on thrombus
formation after photochemical injury. It cannot be excluded,
however, that the effect of DMSO in vivo may be attributable
in part to its ability to impair platelet adherence and
aggregation.36
Figure 6. DMSO inhibits carotid artery TF activity and prevents thrombotic occlusion in a mouse model of photochemical injury. A,
DMSO inhibits TF activity in mouse carotid artery. Values are given as absorbance at 405 nm. **P0.0001 vs PBS treated (vehicle). B,
Transit-time ﬂow recordings of vehicle-treated (PBS) or DMSO-treated mouse carotid artery after photochemical injury in vivo. Laser
injury is initiated at time0 minutes. Uninjured mice are included as an additional negative control. DMSO prevents thrombus formation
(P0.0090 for DMSO-treated vs vehicle-treated; P0.002 for DMSO-treated vs negative control). *P0.001.
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In patients after myeloablative therapy, DMSO is infused
intravenously together with hematopoietic progenitor cells;
under these conditions, DMSO reaches plasma concentrations
of 1.6% (20.0 mmol/L) and only rarely causes adverse
effects.1 The effectiveness of DMSO in inhibiting thrombus
formation is underscored by the low dose we applied in the in
vivo experiments (3.8 mL/kg of a 40% DMSO solution).
Because 10% of a lipophilic substance is resorbed through
the peritoneum within 2 hours,37 the mouse plasma concen-
tration of DMSO is estimated to be 10 times lower than the
maximal concentrations observed in humans after stem cell
transfusion. Moreover, DMSO was still able to prevent
thrombotic occlusion in 50% of mice when applied 5 minutes
after the onset of injury, although this greatly reduces
resorption time and plasma concentration.
Involvement of TF in acute coronary syndromes was
recently underlined by a study that revealed increased levels
of TF antigen and activity in atherectomy specimens from
patients with unstable angina or myocardial infarction com-
pared with those with stable angina.38 Moreover, in acute
coronary syndromes, plasma concentrations of cytokines such
as TNF- and interleukin-6 are increased at the site of
coronary artery occlusion to concentrations high enough to
induce TF in vascular cells.39 For these reasons, inhibition of
TF by DMSO may represent a novel and promising strategy
for targeting thrombosis in acute coronary syndromes. In
addition, the antiproliferative and antimigratory properties of
DMSO, as well as its common use in clinical practice,
underscore its suitability for administration to patients with
acute coronary syndromes as a coating agent for drug-eluting
stents.
Although drug-eluting stents are effective in reducing
restenosis rates after percutaneous coronary intervention
through inhibition of neointima formation and constrictive
remodeling, stent thrombosis remains a concern with these
devices. Indeed, the rate of stent thrombosis observed with
drug-eluting stents is 
2% in controlled clinical trials and
may be higher in “real world” patients.40,41 Moreover, if
thrombosis of such stents occurs, it is associated with a high
morbidity and mortality.42 The present study suggests that
DMSO has the potential to inhibit both neointima formation
and stent thrombosis if applied on a drug-eluting stent. The
known ability of DMSO to inhibit platelet aggregation may
be very important in this context as well.36 The ability of
DMSO to suppress rapamycin and paclitaxel-induced TF
expression is of particular relevance, because this effect of
rapamycin and paclitaxel represents a possible cause of stent
thrombosis in drug-eluting stents.19,25 Indeed, DMSO could
be applied on such stents either alone or in combination with
rapamycin or paclitaxel. Because this application is techni-
cally feasible and appears particularly promising, the poten-
tial beneficial effect of DMSO should be confirmed in a
large-animal model.
In summary, the present study provides evidence that
DMSO specifically suppresses TF expression and activity in
addition to preventing TF-dependent thrombosis in vivo;
furthermore, DMSO inhibits proliferation and migration of
VSMCs and prevents rapamycin- and paclitaxel-induced TF
expression. Because the use of DMSO is established in
different areas of modern medicine, we propose this drug as
a novel strategy for treating acute coronary syndromes; in
particular, DMSO appears to represent an attractive com-
pound for application on drug-eluting stents, either alone or in
combination with rapamycin or paclitaxel.
Figure 7. DMSO inhibits proliferation and migration of VSMCs.
A, DMSO inhibits VSMC proliferation in response to 10% FCS in
a concentration-dependent manner; *P0.05 vs control.
HASMC indicates human aortic smooth muscle cells. B, DMSO
inhibits VSMC migration in response to 10 ng/mL platelet-
derived growth factor in a concentration-dependent manner;
*P0.05 vs control. Four different experiments were performed
in duplicate for each experimental condition. Values are given as
percent of stimulation with mitogen alone. C, Rapamycin (10	7
mol/L) and paclitaxel (10	5 mol/L) enhance thrombin-induced TF
expression in HAECs (*P0.05 for rapamycin or paclitaxel vs
thrombin alone). DMSO blunts both thrombin-induced TF
expression and the effect of rapamycin and paclitaxel on TF
expression. **P0.0001 vs DMSO, DMSO plus rapamycin, and
DMSO plus paclitaxel. Blots are representative of 4 different
experiments.
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CLINICAL PERSPECTIVE
Subacute stent thrombosis is a major clinical concern. Although drug-eluting stents (DES) are effective in reducing
restenosis rates, these stents have not reduced the incidence of stent thrombosis compared with bare-metal stents. Indeed,
the rate of stent thrombosis observed with DES is 
2% in controlled clinical trials and may be higher in “real world”
patients. Rapamycin and paclitaxel are used on DES because they inhibit neointima formation; however, these drugs also
induce expression of tissue factor (TF), a key protein for initiation of thrombus formation; indeed, this represents a possible
cause of stent thrombosis with DES. Therefore, the search for new molecules to cover stents remains important. Dimethyl
sulfoxide (DMSO) is used for preservation of hematopoietic progenitor cells and is infused into patients undergoing bone
marrow transplantation. We observed that DMSO suppresses TF expression and activity and thrombus formation in a
mouse model in vivo; in addition, it inhibits vascular smooth muscle cell proliferation and migration. These data suggest
that DMSO has the potential to inhibit both neointima formation and stent thrombosis if applied on a DES. Given this
profile of action and its routine use in modern clinical practice, we propose DMSO be used to coat DES and treat acute
coronary syndromes. Indeed, DMSO could be applied on DES either alone or in combination with rapamycin or paclitaxel.
Although this application looks promising and technically feasible, the potential beneficial effects of DMSO must be
confirmed in a large-animal model before a clinical trial can be initiated.
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